{"id":"NCT03062280","sponsor":"Neurocrine UK Limited","briefTitle":"A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH","officialTitle":"A Phase III Extension Study of Efficacy, Safety and Tolerability of Chronocort® in the Treatment of Congenital Adrenal Hyperplasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-18","primaryCompletion":"2022-07-13","completion":"2022-07-13","firstPosted":"2017-02-23","resultsPosted":"2024-10-24","lastUpdate":"2024-10-28"},"enrollment":91,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Adrenal Hyperplasia"],"interventions":[{"type":"DRUG","name":"Hydrocortisone","otherNames":[]}],"arms":[{"label":"Chronocort®","type":"EXPERIMENTAL"}],"summary":"Subjects completing study DIUR-005 and those who have already completed study DIUR-003 will be offered the opportunity either to continue Chronocort® therapy or to switch from their current glucocorticoid therapy to Chronocort® in this open-label study.","primaryOutcome":{"measure":"Safety and Tolerability - Number of Participants With Adrenal Insufficiency","timeFrame":"Up to approximately 5 years and 11 months","effectByArm":[{"arm":"Chronocort®","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33527139"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":91},"commonTop":["Fatigue","Headache","Pyrexia","Nasopharyngitis","Vomiting"]}}